AbbVie sets up shop in Singapore
AbbVie is establishing roots in Asia. The drugmaker announced Thursday that it was investing $320 million to build the manufacturing facility in Singapore—its first manufacturing site in all of Asia. The site will be focused on emerging oncology and immunology products.
The company said in a statement it expects the site will be fully operational by 2019 and will employ around 250.
AbbVie split from Abbott Laboratories in January 2013.